Anti-Beta-Catenin antibody
Specifications
| Product Cat#: | AB-06-0510 |
| Product type: | Primary antibody |
| Antigen: | Beta-Catenin |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:5000); Immunocytochemistry (1:20-1:50); Immunohistochemistry (1:20-1:200); Immunoprecipitation (1:20-1:50) |
| Reactivity: | Mouse, Rat and Human |
| Clonality (clone number): | Monoclonal, SA30-04 |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A/G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Beta catenin antibody |
| Beta-catenin antibody | |
| Cadherin associated protein antibody | |
| Catenin (cadherin associated protein), beta 1, 88kDa antibody | |
| Catenin beta 1 antibody | |
| Catenin beta-1 antibody | |
| CATNB antibody | |
| CHBCAT antibody | |
| CTNB1_HUMAN antibody | |
| CTNNB antibody | |
| CTNNB1 antibody | |
| DKFZp686D02253 antibody | |
| FLJ25606 antibody | |
| FLJ37923 antibody | |
| OTTHUMP00000162082 antibody | |
| OTTHUMP00000165222 antibody | |
| OTTHUMP00000165223 antibody | |
| OTTHUMP00000209288 antibody | |
| OTTHUMP00000209289 antibody |
Target information
Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML. Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle.
Provider
Erpantech Laboratory